scholarly journals Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

2021 ◽  
Vol 27 (3) ◽  
pp. S341-S342
Author(s):  
Michael L. Wang ◽  
John M. Rossi ◽  
Javier Munoz ◽  
Andre H. Goy ◽  
Frederick L. Locke ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Clinical Outcomes ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Pharmacological Profile ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase

scholarly journals Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2412-2424 ◽  
Author(s):  
Betty Y. Chang ◽  
Michelle Francesco ◽  
Martin F. M. De Rooij ◽  
Padmaja Magadala ◽  
Susanne M. Steggerda ◽  
...  
Keyword(s):  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Peripheral Blood ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor ◽  
And Migration

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Sign in / Sign up

Export Citation Format

Share Document